The scattering points in a plasma sheath characterized with coupled velocities can cause pulse compression mismatching, which results in displacement and energy diffusion in the one-dimension range profile. To solve this problem, we deduce the echo model of the plasma-sheath-enveloped reentry object. By estimating the coupled velocities, we propose a compensation method to correct the defocus of an inverse synthetic aperture radar (ISAR) image in range dimension to improve the quality of the ISAR images. The simulation results suggest that the echoes from different regions of the surface of the reentry object have various coupling velocities, and the higher the coupled velocity, the more serious the displacement and energy diffusion in the range dimension. Our proposed method can correct the range dimension aberration. Two measurement metrics were used to evaluate the improvement of the compensation method.
Both neoadjuvant and perioperative immunotherapies have emerged as standard-of-care treatments for patients with resectable non-small cell lung cancer (NSCLC). However, the optimal treatment strategy regarding the necessity of the adjuvant phase remains undefined due to a lack of direct head-to-head comparisons. This study thus aimed to quantitatively evaluate whether extending immunotherapy into the adjuvant phase confers a survival benefit over neoadjuvant therapy alone in patients with stage III NSCLC. A systematic search of the PubMed, Embase, Cochrane Library, and Web of Science databases was conducted for randomized controlled trials (RCTs) published as of June 21, 2025. Individual patient data (IPD) were reconstructed from Kaplan-Meier (KM) curves of the eligible studies. The primary end points were event-free survival (EFS) and overall survival (OS). Statistical analyses included stratified log-rank tests, Cox proportional hazards regression, and restricted mean survival time (RMST) analysis. Seven studies (six RCTs and one single-arm phase II trial) involving 1,436 patients with stage III NSCLC were included in the analysis. In the overall population, neoadjuvant and perioperative immunotherapies demonstrated comparable efficacy, with no significant difference in EFS [hazard ratio (HR) =0.99; 95% confidence interval (CI): 0.72–1.36; P=0.94]. Subgroup analysis indicated stage-dependent outcomes: EFS was similar in the stage IIIA cohort (HR =1.04; P=0.87), whereas a nonsignificant advantage for neoadjuvant therapy was observed in the mixed-stage IIIA–IIIB cohort (HR =0.52; 95% CI: 0.27–1.03; P=0.05). In the analysis of OS, which was restricted to the stage IIIA population due to data maturity, no significant difference was found between the two strategies (HR =0.97; 95% CI: 0.58–1.64; P=0.92). The 5-year RMST of OS was 48.51 months for the neoadjuvant group and 47.56 months for the perioperative group (difference =0.95 months; P=0.69). The findings from this IPD-based quantitative analysis suggest that neoadjuvant immunotherapy may yield EFS and OS outcomes comparable to those of perioperative immunotherapy in patients with resectable stage III NSCLC. However, given the indirect nature of the comparison, these results should be considered hypothesis-generating; they provide a rationale for investigating a neoadjuvant-only strategy as a potential de-escalation approach. Future head-to-head trials are warranted to validate these findings, particularly among patients with stage IIIB disease.
Strict privacy regulations restrict access to individual-level clinical trial data, confining secondary evidence synthesis to isolated one-dimensional Kaplan-Meier summaries. Inferring unreported joint distributions from these independent marginals constitutes an ill-posed inverse problem that limits multivariable precision oncology. Conventional algorithms default to the maximum entropy (MaxEnt) prior, which forces uncalibrated conditional independence upon highly collinear variables. This dismantles inherent informational dependencies, yielding unrealistic, “off-manifold” profiles that fundamentally misspecify the data-generating process and distort multivariable credit allocation. Here, we introduce MD-JoPiGo, an open-source computational framework that overcomes this structural unidentifiability by constraining high-dimensional integration within deterministic Fréchet bounds. Drawing on partial identification principles, the algorithm employs quadratically penalized maximum entropy combined with simulated annealing to anchor point estimations within the theoretically observable Fréchet gap. Through causal topology simulations, we demonstrate that the uncalibrated MaxEnt prior suffices for weakly correlated predictors ( r ≤ 0.4) but requires structural calibration to prevent systematic error under high collinearity ( r ≥ 0.6). This topological constraint functions as a variance firewall, ensuring that structural uncertainty and prognostic misallocation remain strictly localized. Extensive Monte Carlo simulations and empirical benchmark analyses—including lung cancer ( n = 228), stage III colon cancer ( N = 929), and CheckMate 227—demonstrate that the framework successfully recovers latent intersectional treatment effects. By unifying topological inference with data generation, this method translates fragmented public evidence into realistic in silico cohorts, supplying the multivariable resolution required for cross-study benchmarking and privacy-preserving Synthetic Control Arm (SCA) construction.
Severe metal artifacts in cervical brachytherapy CT scans obscure critical anatomical structures and applicator geometry. Existing metal artifact reduction